AU7743100A - Stress protein compositions and methods for prevention and treatment of cancer and infectious disease - Google Patents

Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

Info

Publication number
AU7743100A
AU7743100A AU77431/00A AU7743100A AU7743100A AU 7743100 A AU7743100 A AU 7743100A AU 77431/00 A AU77431/00 A AU 77431/00A AU 7743100 A AU7743100 A AU 7743100A AU 7743100 A AU7743100 A AU 7743100A
Authority
AU
Australia
Prior art keywords
cancer
prevention
treatment
methods
infectious disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77431/00A
Inventor
Robert A. Henderson
Latif Kazim
Elizabeth A. Repasky
John R. Subjeck
Xiangyang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Corixa Corp
Original Assignee
Health Research Inc
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc, Corixa Corp filed Critical Health Research Inc
Publication of AU7743100A publication Critical patent/AU7743100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
AU77431/00A 1999-09-30 2000-09-29 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease Abandoned AU7743100A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15682199P 1999-09-30 1999-09-30
US60156821 1999-09-30
US16316899P 1999-11-02 1999-11-02
US60163138 1999-11-02
US21549700P 2000-06-30 2000-06-30
US60215497 2000-06-30
PCT/US2000/027023 WO2001023421A2 (en) 1999-09-30 2000-09-29 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

Publications (1)

Publication Number Publication Date
AU7743100A true AU7743100A (en) 2001-04-30

Family

ID=27496262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77431/00A Abandoned AU7743100A (en) 1999-09-30 2000-09-29 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

Country Status (6)

Country Link
US (2) US6984384B1 (en)
EP (1) EP1216055A2 (en)
JP (1) JP2003510334A (en)
AU (1) AU7743100A (en)
CA (1) CA2386032A1 (en)
WO (1) WO2001023421A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
EP1575526B1 (en) 2002-05-21 2012-06-06 Irun R. Cohen Dna vaccines encoding heat shock proteins
ES2353753T3 (en) * 2002-08-16 2011-03-04 Glycotope Gmbh PROCEDURE FOR THE PRODUCTION OF LISTS OF TUMOR CELLS INDUCED BY TEMPERATURE FOR USE AS IMMUNOGEN COMPOUNDS.
SI1654353T1 (en) 2003-08-18 2013-09-30 Glycotope Gmbh Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
EP1715042B1 (en) * 2004-01-20 2012-08-22 Aichi Prefecture EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME
JP2008048601A (en) * 2004-06-15 2008-03-06 Nippon Kosei Kagaku Kenkyusho:Kk Method for producing therapeutically useful product and system
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
US20060120995A1 (en) * 2004-12-02 2006-06-08 Shah Maulik R Neoadjuvant genetic compositions and methods
US7585945B2 (en) 2006-08-25 2009-09-08 Health Research, Inc. Use of recombinant heat shock protein complexed to kidney cancer antigen
ES2620261T3 (en) * 2006-09-10 2017-06-28 Glycotope Gmbh Use of human myeloid leukemic cells for antibody expression
PL1920781T3 (en) * 2006-11-10 2015-06-30 Glycotope Gmbh Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US8222214B2 (en) 2007-06-01 2012-07-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
AU2014201488B2 (en) * 2007-06-01 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Vaccine for the Prevention of Breast Cancer Relapse
RU2497543C2 (en) * 2007-11-02 2013-11-10 Хелт Рисерч Инк. Compositions and methods for using ca9 protein for immune system stimulation
GB0816242D0 (en) * 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes
WO2010115118A2 (en) * 2009-04-03 2010-10-07 Antigenics, Inc. Methods for preparing and using multichaperone-antigen complexes
RU2014110953A (en) 2011-08-22 2015-09-27 Гликотоп Гмбх MICRO-ORGANISMS BEARING TUMOR ANTIGEN
WO2014093950A1 (en) 2012-12-14 2014-06-19 Virginia Commonwealth University Immune modulator for immunotherapy and vaccine formulation
US20210393700A1 (en) * 2017-11-29 2021-12-23 Figene, Llc Interaction of fibroblasts and immune cells for activation and uses thereof
EP3794041B1 (en) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1 antibody
WO2023056334A1 (en) * 2021-09-30 2023-04-06 The Children's Medical Center Corporation Tlr4 agonist for modulating immune response

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066579A (en) * 1986-12-31 1991-11-19 Genelabs Incorporated HTLV-I peptide antigen and assay
DK0474727T3 (en) * 1989-05-19 1998-01-12 Genentech Inc HER2 extracellular domain
US6268213B1 (en) * 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP1221488A1 (en) 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6015507A (en) * 1994-11-08 2000-01-18 Minolta Co., Ltd. Liquid crystal element having composite layer
EP0851764A4 (en) 1995-08-18 2002-08-07 Sloan Kettering Inst Cancer Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) * 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
CA2231998A1 (en) 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997026910A2 (en) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumour vaccine for immunotherapy of malignant tumours
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6066716A (en) * 1996-09-20 2000-05-23 University Of New Mexico Purified heat shock protein complexes
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
PT941315E (en) * 1996-11-26 2006-06-30 Stressgen Biotechnologies Corp STRESS PROTEINS CONTAINING FUSEO PROTEINS TO INDUCE IMMUNE RESPONSE
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
EP1047451A1 (en) 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
DE69834671T2 (en) * 1997-08-05 2007-05-10 Stressgen Biotechnologies Corp., Victoria Immune response against HPV antigens produced by compositions containing an HPV antigen and a stress protein or an expression vector capable of expressing these proteins
US5888795A (en) * 1997-09-09 1999-03-30 Becton, Dickinson And Company Thermostable uracil DNA glycosylase and methods of use
CA2361009C (en) 1999-01-29 2012-10-23 Corixa Corporation Her-2/neu fusion proteins

Also Published As

Publication number Publication date
WO2001023421A3 (en) 2001-10-25
EP1216055A2 (en) 2002-06-26
WO2001023421A9 (en) 2002-09-26
US7976846B2 (en) 2011-07-12
US6984384B1 (en) 2006-01-10
US20050202035A1 (en) 2005-09-15
WO2001023421A2 (en) 2001-04-05
CA2386032A1 (en) 2001-04-05
JP2003510334A (en) 2003-03-18
WO2001023421B1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU7743100A (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
AUPR638101A0 (en) Composition and method for treatment of disease
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2002312303A1 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU2495200A (en) Compositions and methods for the treatment of tumor
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU2001232345A1 (en) Compositions for preventing and treating digestive diseases
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU4034800A (en) Novel compositions and methods for prevention and treatment of protozoal disease
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU1405001A (en) Treatment of diseases
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase